Inhalation Platform Licensing MAP's proprietary drug particle and inhalation technologies create a scalable platform for partnerships to re-formulate proven drugs into inhaled therapies, enabling faster development and lower risk for potential partners.

Phase Three Momentum Positive results from the first Phase 3 trial of LEVADEX position MAP for potential licensing or co-development deals around migraine treatment, with manufacturing and commercialization readiness to support a potential launch.

Outsourced Manufacturing Fit With a mid-size team and manufacturing focus, MAP could be an attractive CDMO partner for inhalation therapies, offering formulation optimization, device integration, and scalable fill-finish capabilities to larger pharma players.

Financial Partnership Flexibility Healthy revenue scale and available funding create room for milestone-based partnerships, co-development financing, or licensing agreements that reduce upfront risk for both MAP and partner companies.

Global Commercialization Potential MAP's US base combined with a track record in advancing inhaled therapies presents opportunities to partner with global pharmaceutical companies seeking migraine and respiratory delivery expertise, expanding market access and distribution.